SHEET 1 OF 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.


FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
					YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

/AJ/	1.	Bridges et al., "A Late Increase in Free Radical Activity Post Myocardial Infarction," <i>European Heart Journal</i> , 16 (1995), pp. 899-902
	2.	Hayakawa et al., "Alteration of Redox State of Human Serum Albumin in Patients Under Anesthesia and Invasive Surgery," <i>Journal of Chromatography B</i> , 698 (1997), pp. 27-33
	3.	Kadota et al., "Decreased Sulfhydryl Groups of Serum Albumin in Coronary Artery Disease," <i>Japanese Circulation Journal</i> , 55 (Oct. 1991), pp. 937-941
	4.	Lapenna et al., "Impaired Glutathione Biosynthesis in the Ischemic-Reperfused Rabbit Myocardium," <i>FEBS Letters</i> , 391 (1996), pp. 76-78
	5.	Maezawa et al., "Decreased Sulfhydryl Groups in the Reperfused Myocardial Tissue of a Rat Model of Myocardial Infarction," <i>Japanese Circulation Journal</i> , 61 (Feb. 1997), pp. 151-160
	6.	Kuller et al., "The Relation Between Serum Albumin Levels and Risk of Coronary Heart Disease in the Multiple Risk Factor Intervention Trial," <i>American Journal of Epidemiology</i> , 134, No. 11 (1991), pp. 1266-1277
↓	7.	Lesnefsky et al., "Myocardial Sulfhydryl Pool Alterations Occur During Reperfusion After Brief and Prolonged Myocardial Ischemia in Vivo," <i>Circulation Research</i> , 68, No. 2 (Feb. 1991), pp. 605-777
/AJ/	8.	Schoenbach et al., "The Determination of Sulfhydryl Groups in Serum. II. Protein Alterations Associated with Disease," <i>J. Clin. Invest.</i> , 30, No. 7 (July 1951), pp. 762-777

EXAMINER /Amy Juedes/	DATE CONSIDERED 07/29/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SHEET 1 OF 1

FORM PTO-144 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

/AJ/	1	Christodoulou et al.; "A New Structural Transition of Serum Albumin Dependent on the State of Cys34"; <i>Eur. J. Biochem.</i> ; 1994; 225:363-368
/AJ/	2	Gryzunov et al.; "Binding of Fatty Acids Facilitates Oxidation of Cysteine-34 and Converts Copper-Albumin Complexes from Antioxidants to Prooxidants"; <i>Archives of Biochemistry and Biophysics</i> ; 2003; 413:53-66
/AJ/	3	Kashiba-Iwatsuki et al.; "Effect of Nitric Oxide on the Ligand-Binding Activity of Albumin"; <i>Archives of Biochemistry and Biophysics</i> ; September 15, 1997; 345(2):237-242

EXAMINER 07/29/2007	DATE CONSIDERED 07/29/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



INFORMATION DISCLOSURE STATEMENT BY APPLICANT Substitute for form 1449A/PTO				Complete If Known	
				Application Number	10/680,935
				Filing Date	October 2, 2003
				First Named Inventor	BAR-OR et al.
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	4172-81

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ ; Number ⁴ ; Kind Code ⁵ (if known)					

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. ¹	
/AJ/	1	Hunter; "Protein Kinases and Phosphatases: The Yin and Yang of Protein Phosphorylation and Signaling"; <i>Cell</i> ; 1995; 80:225-236; 2 pp.
/AJ/	2	Mulvihill et al.; "Inflammation in Acute Coronary Syndromes"; <i>Heart</i> ; 2002; 87:201-204
/AJ/	3	Shanley; "Phosphatases: Counterregulatory Role in Inflammatory Cell Signaling"; <i>Crit Care Med</i> ; 2002; 30(1) Suppl:S80-S88

Examiner Signature	/Amy Juedes/	Date Considered	07/29/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

J:\4172\81\1449-006.wpd

page 1 of 2

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10680935
Filing Date	2003-10-02
First Named Inventor	David Bar-Or
Art Unit	1645
Examiner Name	Amy Juedes
Attorney Docket Number	4172-81

U.S. PATENTS[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)**U.S. PATENT APPLICATION PUBLICATIONS**[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)**FOREIGN PATENT DOCUMENTS**[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/AJ/	1	2004034060	WO	A2	2004-04-22	Van Eyk, et al.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

[Add](#)**NON-PATENT LITERATURE DOCUMENTS**[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10680935
Filing Date		2003-10-02
First Named Inventor	David Bar-Or	
Art Unit	1645	
Examiner Name	Amy Juedes	
Attorney Docket Number	4172-81	

	1		☐
--	---	--	--------------------------


If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Amy Juedes/	Date Considered	07/29/2007
--------------------	--------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.



SHEET 1 OF 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
/AJ/	1	2004/0067595	4/8/2004	Davies et al.	436	107	8/24/2001
/AJ/	2	5,459,076	10/17/1995	Stamler et al.	436	116	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
/AJ/	3	WO 03/076946	9/18/2003	PCT	G01N	33/68		
/AJ/	4	WO 98/29452	7/9/1998	PCT	C07K	16/18	(Abstract Only)	
/AJ/	5	WO 96/04311	2/15/1996	PCT	C07K	16/18		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

/AJ/	6	Beck et al.; "Direct Observation of Covalent Adducts with Cys34 of Human Serum Albumin Using Mass Spectrometry"; <i>Analytical Biochemistry</i> , 325 (2004); pp. 326-336

EXAMINER /Amy Juedes/	DATE CONSIDERED 07/29/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SHEET 1 OF 45

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
4172-81SERIAL NO.
10/680,935INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANT
Bar-Or et al.FILING DATE
October 2, 2003

GROUP ART

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
/AJ/	A1.	2002/0049307 A1	4/25/2002	Aebersold et al.	530	409	10/18/2001
	A2.	6,309,888	10/30/2001	Holvoet et al.	436	71	
	A3.	5,962,245	10/5/1999	Li et al.	435	18	
	A4.	5,601,985	2/11/1997	Trojanowski et al.	435	7.1	
	A5.	5,980,929	11/9/1999	de Juan, Jr.	424	427	
	A6.	5,710,008	1/20/1998	Jackowski	435	7.4	
	A7.	5,227,307	7/13/1993	Bar-Or et al.	436,	63	
	A8.	6,475,743	11/5/2002	Bar-Or et al.	435	7.1	
	A9.	6,492,179	12/10/2002	Bar-Or et al.	436	74	
	A10.	6,121,003	9/19/2000	Vanmechelen et al.	435	7.1	
	A11.	6,210,976	4/3/2001	Sabbadini	436	518	
	A12.	5,914,242	6/22/1999	Honkanen et al.	435	7.71	
	A13.	6,579,687	6/17/2003	Buechler et al.	435	7.92	
↓	A14.	5,947,124	9/7/1999	Buechler et al.	128	898	
/AJ/	A15.	2003/0109420 A1	6/12/2003	Valkirs et al.	514	2	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
/AJ/	A16.	WO 93/08302	4/29/1993	PCT				
	A17.	EP 0 616 032 A2	9/21/1994	EPO				
	A18.	WO 94/13795	6/23/1994	PCT				
	A19.	WO 95/17429	6/29/1995	PCT				
	A20.	EP 0 526 150 B1	6/12/1996	EPO			X (abstract only)	
	A21.	WO 96/34977 A1	11/7/1996	PCT			(abstract only)	
	A22.	EP 0 823 943 B1	7/28/1999	EPO			X (abstract only)	
	A23.	WO 99/38012	7/29/1999	PCT				
	A24.	WO 00/20840	4/13/2000	PCT				
	A25.	WO 00/20454	4/13/2000	PCT				
	A26.	WO 00/14546	3/16/2000	PCT				
	A27.	JP 2001 258593 A2	9/25/2001	Japan			X (abstract only)	
	A28.	WO 01/71024 A1	9/27/2001	PCT			(abstract only)	
	A29.	AU 142741 A5	10/3/2001	Australia			(abstract only)	
	A30.	WO 02/089656	11/14/2002	PCT				
/AJ/	A31.	WO 02/16947	2/28/2002	PCT				

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

	A32.	WO 02/066988	8/29/2002	PCT				
/AJ/	A33.	WO 03/025571	3/27/2003	PCT				
/AJ/	A34.	WO 03/00182	1/3/2003	PCT				
/AJ/	A35.	WO 03/058249	7/17/2003	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

/AJ/	A36.	Adamcova et al., <i>Physiol. Res.</i> 1999, 48:235-247
	A37.	Andreasson et al., <i>Acta Neurol. Scand. Suppl.</i> 2003, 179:47-51, Abstract only, from PubMed - PMID:12603251
	A38.	Antipenko et al., <i>Vopr Med Khim</i> 1981, 27(4):492-5, Abstract only, from PubMed - PMID:6270907
	A39.	Atar et al., <i>Ugeskr Læger</i> 2003, 165(2):116-20, Abstract only, from PubMed - PMID:12553091
	A40.	Bartel et al., <i>Biomed Biochim Acta</i> 1989, 48(2-3):S108-13, Abstract only, from PubMed - PMID:2525030
	A41.	Blennow et al., <i>Mol Neurobiol</i> 2001, 24(1-3), Abstract only, from PubMed - PMID:11831556
✓	A42.	Borutaite et al., <i>J Mol Cell Cardiol</i> 1996, 28(10):2195-2201, Abstract only, from PubMed - PMID:8930814
/AJ/	A43.	Brennan et al., <i>Biochim Biophys Acta</i> 1999, 1443(1-2):321-326, Abstract only, from PubMed - PMID:10446380
	~~A44.~~	~~Dalrymple et al., <i>J Mol Neurosci</i> 2002, 19(3):295-299, Abstract only, from PubMed - PMID:12540055~~
/AJ/	A45.	Eikelenboom et al., <i>Trends Pharmacol. Sci.</i> 1994, 15:447-450
/AJ/	A46.	England et al., <i>Biomed Biochim Acta</i> 1987, 46(5):369-380, Abstract only, from PubMed - PMID:2822035
/AJ/	A47.	Fath et al., <i>J Neurosci</i> 2002, 22:2977-9741, Abstract only, from PubMed - PMID:12427828
	~~A48.~~	~~Goedert et al., <i>Biochem J</i> 1994, 301(1-3):671-677, Abstract only, from PubMed - PMID:7519652~~
/AJ/	A49.	Hesse et al., <i>Neuroscience Letters</i> 2001, 297:187-190
	~~A50.~~	~~Ingleton et al., <i>Somatos. Mot. Behav.</i> 1999, 10:442-445~~

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

	A51.	~~Jaquet et al., Eur J Biochem 1995, 231(2):486-490, Abstract only, from PubMed - PMID:7635159~~
	A52.	~~Krause et al., Gen Physiol Biophys 1984, 3:193-199, Abstract only, from PubMed - PMID:6479578~~
	A53.	Labugger et al., Circulation 2000, 102:1221-1226
/AJ/	A54.	Li et al., Am. J. Physiol. 1997, 272:H360-H370
	A55.	~~Lim et al., Analytical Biochemistry 2001, 295:45-56~~
/AJ/	A56.	Lindhout et al., Biochemistry 2002, 41(23):7267-7274, Abstract only
/AJ/	A57.	Magrez et al., www.currentdrugdiscovery.com, September 2002, pp.23-27
	A58.	~~McDonough et al., Circulation Research 1999, 84:9-20~~
/AJ/	A59.	Moritz et al., J Biol Chem 2001, 276(11):8244-8253, Abstract only, from PubMed - PMID:11098061
	A60.	Opie et al., Jpn Circ J 1978, 42(11):1223-1247, Abstract only, from PubMed - PMID:34741
	A61.	Parnetti et al., Neurol Sci 2001, 22(1):77-78, Abstract only, from PubMed - PMID:11487210
	A62.	Reimenschneider et al., Mol Psychiatry 2003, 8(3):343-347, Abstract only, from PubMed - PMID:12660807
	A63.	Sang et al., Neurosci Lett 2001, 312(3):141-144, Abstract only, from PubMed - PMID:11602330
/AJ/	A64.	Schmidtman et al., FEBS Lett 2002, 513(2):389-293, Abstract only, from PubMed - PMID:11904166
	A65.	~~Sjogren et al., J Neurol Neurosurg Psychiatry 2001, 70(5):624-630, Abstract only, from PubMed - PMID:11309456~~
/AJ/	A66.	Teunissen et al., Neurobiology of Aging 2002, 23:485-508
/AJ/	A67.	Togawa et al., Biochem Biophys Res Commun 2000, 277(3):668-674, Abstract only, from PubMed - PMID:11062011
/AJ/	A68.	Vandermeeren et al., J. Neurochem 1993, 61(5):1828-1834, Abstract only, from PubMed - PMID:8228996
	A69.	~~Van Everbroeck et al., J Neurol Neurosurg Psychiatry 2002, 73(1):75-81, Abstract only, from PubMed - PMID:12062034~~
/AJ/	A70.	Vanmechelen et al., Neurosci Lett 2000, 285(1):49-52, Abstract only, from PubMed - PMID:10788705
/AJ/	A71.	Ward et al., J Biol Chem, August 30, 2002 (epub ahead of print), Abstract only, from PubMed - PMID:12207022

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

/AJ/	A72.	Westwood et al., <i>Biochem.</i> 198, 197:185-193
------	------	---

EXAMINER /Amy Juedes/	DATE CONSIDERED 07/29/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SHEET 1 OF 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
/AJ/	AA	6,444,432	9/3/2002	Kleinfeld	435	7.8	
/AJ/	AB	6,156,521	12/5/2000	Buechler et al.	435	7.1	
/AJ/	AC	5,470,750	11/28/1995	Bar-Or	436	63	
/AJ/	AD	5,055,389	10/8/1991	Bar-Or et al.	435	4	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
/AJ/	AE	WO 01/11371 A2, A3	2/15/2001	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	AF	Al-Hillawi et al., "Phosphorylation-specific antibodies for human cardiac troponin-I," <i>European Journal of Biochemistry</i> 1998, 256:535-560
/AJ/	AG	Altschule et al., "Orthohydroxyhippuric (salicyluric) acid - its physiologic and clinical significance," <i>Clinical Pharmacology and Therapeutics</i> 1974, 15(2):111-117
/AJ/	AH	Austad et al., "Salicyluric Acid as a Metabolite of L-Tryptophan," <i>Nature</i> 1965, 207(4998):757
/AJ/	AI	Bereznikova et al., "Monoclonal Antibodies Affected by Cardiac Troponin I Phosphorylation: Is Part of Troponin in the Blood of Myocardial Infarction Patients Phosphorylated?" Poster Abstracts, IFCC-WorldLab '99 - Firenze, 6-11 June 1999, Cardiac Markers, <i>Clin. Chem Lab Med</i> 1999; 37; Special Supplement, S 448

EXAMINER /Amy Juedes/	DATE CONSIDERED 07/29/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

/AJ/	AJ	Holvoet et al., "Malondialdehyde-Modified LDL as a Marker of Acute Coronary Syndromes," <i>J. American Medical Association</i> 1999, 281(18):1718-1721
	AK	Kaplán et al., "Effect of myocardial stunning on thiol status, myofibrillar ATPase and troponin I proteolysis," <i>Molecular and Cellular Biochemistry</i> 2002, 233:145-152
	AL	Katrakha et al., "Biochemical Factors Influencing Measurement of Cardiac Troponin I in Serum," <i>Clin. Chem. Lab. Med.</i> 1999, 37(11/12):1091-1095
	AM	Katrakha et al., "Degradation of cardiac troponin I: implication for reliable immunodetection," <i>Clin. Chem.</i> 1998, 44(12):2433-40, Abstract only, from PubMed -PMID:9836709
	AN	Koroma et al., "Changes Associated with Tyrosine Phosphorylation During Short-Term Hypoxia in Retinal Microvascular Endothelial Cells in Vitro," <i>Journal of Cellular Biochemistry</i> , 59:123-132
	AO	Liao et al., "Time-resolved tryptophan emission study of cardiac troponin I," <i>Biophysical Journal</i> 1992, 63:986-995
	AP	Litersky et al., "Phosphorylation by cAMP-dependent Protein Kinase Inhibits the Degradation of Tau by Calpain," <i>Journal of Biological Chemistry</i> 1992, 267(3):1563-1568
	AQ	Litersky et al., "Phosphorylation of τ In Situ: Inhibition of Calcium-Dependent Proteolysis," <i>Journal of Neurochemistry</i> 1995, 65(2):903-911
↓	AR	Matejovicova et al., "Phosphorylation by protein kinases A and C of myofibrillar proteins in rabbit stunned and non-stunned myocardium," <i>Journal of Molecular and Cellular Cardiology</i> 1997, 29(12):189-202 Abstract only, from PubMed -PMID:9441826
/AJ/	AS	Stull et al., "Phosphorylation of Cardiac Troponin by Cyclic Adenosine 3':5'-Monophosphate-dependent Protein Kinase," <i>Journal of Biological Chemistry</i> 1977, 252(3):851-857

EXAMINER /Amy Juedes/	DATE CONSIDERED 07/29/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	